Chris Degnan - 08 Oct 2025 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role: Chief Financial Officer
Signature: /s/ Jason D. Smith, Attorney-in-Fact
Issuer symbol: URGN
Transactions as of: 08 Oct 2025
Net transactions value: -$37,121
Form type: 4
Filing time: 09 Oct 2025, 13:37:33 UTC
Previous filing: 09 Oct 2024
Next filing: 03 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Degnan Chris	Chief Financial Officer	400 ALEXANDER PARK DRIVE, PRINCETON	/s/ Jason D. Smith, Attorney-in-Fact	09 Oct 2025	0001741968

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	URGN	Ordinary Shares	Options Exercise		+4,483			4,483	08 Oct 2025	Direct	F1
transaction	URGN	Ordinary Shares	Sale	$37,121	-2,203	-49%	$16.85	2,280	08 Oct 2025	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	URGN	Restricted Stock Units	Options Exercise	$0	-4,483	-33%	$0.000000	8,967	08 Oct 2025	Ordinary Shares	4,483		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2	Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
F3	The reporting person was granted RSUs on October 8, 2024 representing 13,450 ordinary shares. The RSUs will vest in three equal annual installments from October 8, 2025.